一、合作情况 禾元生物是一家创新型生物医药企业，拥有领先的植物生物反应器技术平台， 创建了具有自主知识产权的水稻胚乳细胞生物反应器高效重组蛋白表达平台 （OryzHiExp）和重组蛋白纯化技术平台（OryzPur），建立了完善的药品、药用辅料 及科研试剂的产业化体系，并于 2023 年 12 月获得由湖北省药品监督管理局颁发 的《药品生产许可证》。 2022 年，公司以 3.85 亿元人民币的自有资金按每股 19.24 元的价格认购 禾元生物新发行的 Pre-IPO 轮普通股 20,010,395 股，截至目前，公司直接持 有禾元生物 7.47%的股份。2024 年，双方签署《禾元生物药品区域经销协议》， 禾元生物委托贝达药业在约定区域内独家经销奥福民®。具体内容详见公司披 露在巨潮资讯网上的相关公告（公告编号：2022-019、2022-023、2022-041、 2024-069）。 证券代码：300558 证券简称：贝达药业 公告编号：2025-050 贝达药业股份有限公司 关于参股公司禾元生物新药奥福民获批上市的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述 ...

Core Viewpoint - The AI Fund Yinhua Medical Health Quantitative Stock Initiation A (005237) reported a profit of 704,200 yuan in Q2 2025, with a net value growth rate of 3.25% for the period, indicating a positive performance in the medical and healthcare sector [2]. Fund Performance - As of the end of Q2 2025, the fund's scale was 22.77 million yuan [13]. - The fund's unit net value as of July 17 was 1.253 yuan [2]. - The fund's performance over various time frames includes: - 3-month net value growth rate: 12.97%, ranking 47 out of 54 comparable funds [2]. - 6-month net value growth rate: 18.70%, ranking 47 out of 54 comparable funds [2]. - 1-year net value growth rate: 19.99%, ranking 45 out of 53 comparable funds [2]. - 3-year net value growth rate: -15.15%, ranking 29 out of 46 comparable funds [2]. Risk Metrics - The fund's Sharpe ratio over the past three years was -0.1083, ranking 30 out of 46 comparable funds [7]. - The maximum drawdown over the past three years was 39.37%, ranking 24 out of 46 comparable funds, with the largest single-quarter drawdown occurring in Q1 2021 at 25.15% [8]. Investment Strategy - The fund focuses on long-term investments in pharmaceutical and healthcare stocks, with a strong emphasis on the innovative drug industry [2]. - The average stock position over the past three years was 89.19%, with a peak of 92.5% at the end of H1 2025 and a low of 85.16% at the end of H1 2024 [11]. Top Holdings - As of the end of Q2 2025, the fund's top ten holdings included: - Heng Rui Medicine - WuXi AppTec - Mindray Medical - BeiGene - East China Pharmaceutical - Kelun Pharmaceutical - Baillie Gifford - Betta Pharmaceuticals - Zai Lab - Kailai Ying [16].

Market Sentiment - The current market sentiment score is 84, indicating an "overheated" market condition [2][10][21] - Historical trends show that when sentiment is below or near 30, the market tends to find support, while above 90, resistance is likely [10] Hot Themes Tracking - **Robotics Theme**: The government is promoting entrepreneurship, with significant contracts awarded for humanoid biped robots, totaling 124 million yuan. Related stocks include Wolong Electric Drive and Changsheng Bearing [7] - **RDA Theme**: The Shanghai Data Exchange has introduced the RDA paradigm, emphasizing the integration of real data assets with physical assets. Related stocks include Tongxingbao and Wanda Information [7] - **Innovative Pharmaceuticals Theme**: New measures from the National Healthcare Security Administration support the use of medical insurance data in drug development. Related stocks include Heng Rui Medicine and Betta Pharmaceuticals [7] Capital Flow Analysis - **Net Inflow**: The top ten stocks with the highest net inflow include Changshan Beiming and Runhe Software, with inflows of 201 million yuan and 93 million yuan respectively [11] - **Net Buy in Financing**: New Yi Sheng leads with a net buy of 56 million yuan, followed by Changshan Beiming with 34 million yuan [12] - **Net Outflow**: The top ten stocks with the highest net outflow include Zhongdian Port and ST Huatuo, with outflows of 51 million yuan and 39 million yuan respectively [13] Industry Insights - The computer and electronic sectors are currently attracting significant capital inflow, while industries like banking and environmental protection are experiencing net outflows [16][17][22]

Group 1 - The market sentiment index from Huaxin Securities indicates a score of 73, categorizing the market as "relatively hot," suggesting a positive outlook for investments [5][10][22] - Recent themes in the market include robotics, RDA (Real Data Assets), and innovative pharmaceuticals, with specific projects and government support driving interest in these sectors [6][10] - The robotics theme is highlighted by a significant procurement project worth 124 million yuan for humanoid biped robots, indicating strong growth potential in this area [6] Group 2 - The RDA theme emphasizes the integration of real data assets with physical assets, enhancing the authenticity and value of data, which could lead to new investment opportunities [6] - The innovative pharmaceuticals sector is supported by new measures from the National Healthcare Security Administration, promoting the use of medical insurance data for drug development, which may benefit companies in this field [6] - Key companies mentioned in the robotics sector include Wolong Electric Drive and Changsheng Bearing, while in the RDA sector, Tongxingbao and Wanda Information are highlighted, and in innovative pharmaceuticals, Heng Rui Medicine and Bei Da Pharmaceutical are noted [6]

Investment Rating - The report maintains a "Buy" rating for the industry, indicating an expected investment return exceeding 15% over the next 6-12 months [49][56]. Core Insights - The report identifies a turning point in the innovative drug industry, driven by overseas growth and the opening of the domestic market, suggesting a significant growth phase ahead [34]. - The industry is transitioning from capital-driven to profit-driven growth, with a dual recovery in performance and valuation expected [47][49]. - Key factors include the commercialization of innovative products, the acceleration of clinical data breakthroughs, and the introduction of supportive payment policies [50][49]. Summary by Sections Section 1: Validation of the Turning Point in the Innovative Drug Industry - The innovative drug industry in China is entering a recovery phase, characterized by a "profit year" and the implementation of supportive payment policies [5][10]. - The report highlights a significant increase in the number of innovative drug companies achieving over 500 million yuan in revenue, indicating a robust growth trajectory [21][22]. - The domestic market for innovative drugs is projected to reach a scale of 1 trillion yuan by 2035, with innovative drugs expected to account for 30% of the market [30][32]. Section 2: Core Technology Cycle Configuration - The next generation of immunotherapy is anticipated to drive a new round of biotechnology cycles, with a focus on product strength and clinical demand [37][40]. - The report emphasizes the importance of selecting stocks based on technology cycles, product strength, and clinical needs [44]. Section 3: Investment Recommendations - The report suggests focusing on pharmaceutical companies transitioning to innovation, which are expected to see performance and valuation increases [50]. - It also highlights biotech companies with validated research platforms and potential for overseas product registrations as key investment opportunities [50].

Core Viewpoint - The overdue payment of 180 million yuan by Betta Pharmaceuticals to Yifang Biotech for the innovative lung cancer drug, Beifu Tian, has highlighted the survival pressures faced by both companies and raised concerns about the credit system in the innovative drug industry [1][9]. Group 1: Payment Dispute Details - Yifang Biotech disclosed that Betta Pharmaceuticals has owed 180 million yuan for nearly two years, despite multiple communications and a formal payment reminder sent at the end of 2024 [1][2]. - The cooperation agreement between Yifang Biotech and Betta Pharmaceuticals, established in December 2018, stipulated that Betta would pay a total of 230 million yuan in initial and milestone payments for the drug's development and commercialization [1][2]. - Betta Pharmaceuticals initially paid 55.3 million yuan in 2019, but subsequent milestone payments totaling 180 million yuan were delayed due to claims of "funding arrangements" [2][4]. Group 2: Financial Implications for Yifang Biotech - Yifang Biotech's revenue for 2024 was approximately 169 million yuan, entirely derived from technology licensing and cooperation, making the overdue payment critical for its funding [4][9]. - The company has recognized a bad debt provision of 18 million yuan, reflecting its expectation of non-receipt of the overdue payment [1][4]. Group 3: Financial Condition of Betta Pharmaceuticals - Betta Pharmaceuticals reported a revenue of 2.892 billion yuan and a net profit of 403 million yuan for 2024, with a year-on-year increase of 17.74% and 15.67%, respectively [7][8]. - The company has faced significant cash flow pressures, with a 37.23% decrease in cash reserves to 472 million yuan by the end of 2024, and a current ratio below 1 for three consecutive years [7][8]. Group 4: Market Competition and Challenges - Beifu Tian, as a third-generation EGFR inhibitor, faces intense competition from established products like Osimertinib and Aumolertinib, which has impacted its market performance [5][6]. - The sales performance of Betta's other products has also been under pressure, with significant declines in sales growth and profit margins [5][6]. Group 5: Industry Credit System Concerns - The overdue payment issue has sparked discussions about the credit system in the innovative drug industry, emphasizing the need for transparency and trust in business collaborations [9][10]. - Experts have pointed out the risks associated with unclear contract terms and the importance of financial planning and trust in maintaining long-term partnerships [10].

Core Viewpoint - The pharmaceutical sector remains active, with a focus on leading pharmaceutical companies and the performance of the drug ETF (562050), which tracks the CSI Pharmaceutical Index and has shown significant gains recently [1][3]. Group 1: Pharmaceutical Sector Performance - The drug ETF (562050) opened significantly higher, rising nearly 1% and achieving over 14 million yuan in real-time transactions [1]. - Innovation drug stocks are leading the market, with Lijun Group rising over 6% and Huahai Pharmaceutical increasing over 4% [3]. - The first dynamic adjustment of the medical insurance and commercial insurance innovative drug catalog is set to launch, addressing the high-cost payment challenges for innovative drugs [3]. Group 2: Policy and Market Drivers - The policy emphasizes commercial health insurance as a key payer for innovative drugs, with the first catalog expected to be implemented in October [3]. - The total transaction value of innovative drug License-out deals in China surpassed 66 billion USD in the first half of 2025, with cutting-edge technologies like ADC and bispecific antibodies accounting for over 60% [3]. - The pharmaceutical sector is experiencing a "golden triangle" of drivers: relaxed payment policies, technology export, and rigid demand [3]. Group 3: Earnings Forecasts - All eight constituent stocks of the drug ETF that have released mid-year earnings forecasts are expected to report profits, with expected net profit growth rates exceeding 200% for companies like Buchang Pharmaceutical and Darentang [3][4]. - Specific forecasts include Buchang Pharmaceutical with a lower net profit estimate of 488 million yuan and a growth rate of 110.88%, while Darentang is expected to have a lower estimate of 1.84 billion yuan with a growth rate of 180% [4].

Group 1 - The report indicates that the current market sentiment score is 62, categorizing it as "relatively hot," suggesting a positive market outlook and potential for upward movement [5][10][22] - The report highlights three key themes: robotics, RDA (Real Data Assets), and innovative pharmaceuticals, each with specific developments and related companies [6][10] - In the robotics sector, significant contracts have been awarded, such as a 124 million yuan project for humanoid biped robots, indicating strong growth potential in this area [6] Group 2 - The RDA theme emphasizes the integration of real data with physical assets, enhancing the verification and value of these assets, which could lead to new investment opportunities [6] - The innovative pharmaceuticals theme is supported by new measures from the National Healthcare Security Administration to promote high-quality development, indicating a favorable regulatory environment for related companies [6] - The report lists specific companies associated with each theme, such as Wolong Electric Drive and Changsheng Bearing for robotics, Tongxingbao and Wanda Information for RDA, and Heng Rui Medicine and Bei Da Pharmaceutical for innovative drugs [6]

Group 1 - CITIC Construction Investment expects a net profit of 4.43 billion to 4.57 billion yuan for the first half of 2025, representing a year-on-year increase of 55%-60% [1] - New Hope anticipates a net profit of 680 million to 780 million yuan for the first half of 2025, recovering from a loss of 1.217 billion yuan in the same period last year [2] - Foton Motor forecasts a net profit of approximately 777 million yuan for the first half of 2025, marking an increase of about 87.5% year-on-year [7] Group 2 - North New Road and Bridge expects a net loss of 70 million to 85 million yuan for the first half of 2025 [2] - Nanwei Co. anticipates a net loss of 12 million to 16 million yuan for the first half of 2025 [3] - Hanhua Technology projects a net loss of 45 million to 60 million yuan for the first half of 2025, widening the loss by 11.42%-18.10% compared to the previous year [6] Group 3 - Songlin Technology expects a net profit of 90 million to 95 million yuan for the first half of 2025, a decrease of 57.06%-59.32% year-on-year [4] - Fuchun Environmental Protection anticipates a net profit of 178 million to 207 million yuan for the first half of 2025, representing a year-on-year increase of 80%-110% [18] - Ansteel Group forecasts a net loss of 1.144 billion yuan for the first half of 2025, a reduction in loss of approximately 57.46% compared to the previous year [20][22] Group 4 - China Wuyi expects a net loss of 80 million to 104 million yuan for the first half of 2025, a significant decline compared to the previous year [28] - Meikailong anticipates a net loss of 1.59 billion to 1.92 billion yuan for the first half of 2025 [26] - Aijian Group projects a net profit of 140 million yuan for the first half of 2025, a decrease of 33.26% year-on-year [27]

Group 1 - The report indicates that the current market sentiment score is 75, categorized as "relatively hot," suggesting a positive market outlook and potential for upward movement in stock prices [6][10]. - The report highlights three key themes: robotics, RDA (Real Data Assets), and innovative pharmaceuticals, each with specific developments and related stocks [7]. - In the robotics sector, significant contracts have been awarded, such as a 124 million yuan project for humanoid biped robots, indicating growth potential in this industry [7]. Group 2 - The RDA theme emphasizes the integration of real data with physical assets, enhancing the verification and value of these assets, which could lead to investment opportunities in related companies [7]. - The innovative pharmaceuticals theme is supported by new measures from the National Medical Insurance Administration to promote high-quality development, which may benefit companies in this sector [7]. - The report lists specific stocks related to each theme, such as Wolong Electric Drive and Changsheng Bearing for robotics, Tongxingbao and Wanda Information for RDA, and Heng Rui Medicine and Bei Da Pharmaceutical for innovative drugs [7].